Related Experiment Video
Updated: Jun 7, 2025
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.0K
Modulation of GABAergic neurons in acute epilepsy using sonogenetics
Thi-Nhan Phan1, Ching-Hsiang Fan2, Hsien-Chu Wang3
1Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan.
Summary
This study introduces sonogenetics as a noninvasive epilepsy treatment. Ultrasound stimulation of engineered neurons suppressed seizure activity by 50% in rats, offering a safe new therapeutic approach.
Area of Science:
- Neuroscience
- Biotechnology
- Medical Engineering
Background:
- Epilepsy treatment faces limitations with current invasive methods like surgery and deep brain stimulation.
- Existing neuromodulation techniques often have off-target effects and limited precision.
- There is a need for noninvasive, targeted therapies for epilepsy management.
Purpose of the Study:
- To investigate sonogenetics as a noninvasive method for epilepsy treatment.
- To selectively stimulate γ-aminobutyric acid (GABA)ergic neurons using ultrasound.
- To evaluate the efficacy and safety of sonogenetic neuromodulation in an epilepsy rat model.
Main Methods:
- Utilized sonogenetics with an engineered auditory-sensing protein (mPrestin N7T, N308S) to target GABAergic neurons.
- Administered 0.5-MHz transcranial ultrasound to activate engineered neurons in the amygdala.
- Employed a pentylenetetrazole-induced rat model to mimic epileptiform activity.
- Conducted electrophysiological recordings to assess neuromodulation and seizure suppression.
Main Results:
- Sonogenetic activation of GABAergic neurons modulated epileptiform activity by 50%.
- Achieved persistent seizure suppression for up to 60 minutes post-treatment.
- Confirmed effective neuromodulation without observable tissue damage, inflammation, or apoptosis.
- Demonstrated the safety and efficacy of the noninvasive sonogenetic approach.
Conclusions:
- Sonogenetics offers a promising noninvasive alternative for epilepsy management.
- Targeting GABAergic neurons via ultrasound provides precise and safe neuromodulation.
- This approach represents a significant advancement in developing novel epilepsy therapies.
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
334
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
334
01:14Antiepileptic Drugs: Glutamate Antagonists
284
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
284
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
253
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
253
01:24Arteries of the Lower Limbs
178
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
178
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K